A drug discovery startup that uses proprietary technology to analyze molecular motion, uncovering previously untargeted disease-causing factors and developing therapeutic drugs. We conduct integrated research from basic studies to clinical development, aiming to create novel treatments.
[画像1: https://prtimes.jp/i/112397/6/resize/d112397-6-c5097506b43e9247a435-0.jpg ] ■企業概要 モルミルは、細胞内の分子の状態が変化することが疾病の兆候であることに注目し、その原因となる分子の動きを...
[画像: https://prtimes.jp/i/112397/5/resize/d112397-5-992c8af6c4f75cca2814-0.jpg ] モルミル（所在地：奈良県橿原市、代表取締役：森 英一朗）は、ALSを含む神経難病の治療薬開発に取り組んでおります。202...
[画像1: https://prtimes.jp/i/112397/4/resize/d112397-4-3f3b57f01653cc5b497b-0.png ] モルミル（所在地：奈良県橿原市、代表取締役：森 英一朗）は、これまでに奈良県立医科大学・産業技術総合研究所・徳島...
[画像1: https://prtimes.jp/i/112397/3/resize/d112397-3-a58a01245dcc35a22286-0.jpg ] モルミル（所在地：奈良県橿原市、代表取締役：森 英一朗）は、2022年6月の設立から1周年を迎えました。これまでに奈良...
[画像: https://prtimes.jp/i/112397/2/resize/d112397-2-518ceaf5c56d7a130b4e-1.png ]   岸田内閣も掲げる「科学技術立国の実現」に必要不可欠な1000名以上の有期雇用の研究人材が、今年3月末時点...
[画像1: https://prtimes.jp/i/112397/1/resize/d112397-1-5c2823994592d0265a04-4.jpg ] 現代生命科学の大きな命題「分子の動きを見る」ことが可能になれば、様々な生命現象・病態の解明に繋がることが期待...
A drug discovery venture tackling next-generation cancer treatment using marine-derived compounds that improve tumor hypoxia while minimizing side effects. Already commercialized as veterinary medicine, it supports the lives of both humans and pets.
BEL, Inc. is a deep-tech company specializing in materials science and surface engineering, focusing on the development and social implementation of advanced functional surfaces with antibacterial, antiviral, and anti-biofilm properties. The company integrates polymer science, additive manufacturing (3D printing), and surface microstructure control to create next-generation functional coatings for applications in medical devices, infrastructure, environmental systems, and marine environments. BEL actively promotes international collaboration with universities, research institutes, and industrial partners, aiming to advance materials innovation by integrating materials science with digital technologies such as data science and digital twin methodologies.
Our key product is Enteral Ventilation (EVA) technology, that supplies liquid oxygen to premature babies with serious respiratory problems through Gut-Mediated Oxygen Delivery. The program is at the clinical trial stage.
A startup from UCF’s School of Medicine applying exosome technology to regenerative medicine, drug delivery, non-invasive diagnostics, and medical device development. It aims to improve quality of life through innovative healthcare solutions for intractable diseases.